Heron (HRTX) Gets Green Light From FDA

Posted on

Heron Therapeutic Inc’s long acting injection Sustol, to prevent chemotherapy induced nausea and vomiting had been twice rejected until finally being approved by the U.S. Food and Drug Administration.

This marks the company’s first regulatory approval and boy did investors love the news.

Shares rose as much as 21 percent to $24 on Wednesday.

Heron’s Sustol can protect patients for five days, the company said on Wednesday. Other treatments are usually effective for 48 hours or less.

Heron said Sustol was approved in combination with other agents to prevent nausea and vomiting associated with some forms of chemotherapy, excluding platinum-based regimens.

According to National Institute of Health, nausea and vomiting, one of the most acute side effects of chemotherapy, occurs in up to 80 percent of patients and is the leading cause of patients discontinuing treatment.

Disclaimer: We have no position in Heron Therapeutics Inc. (NASDAQ: HRTX) and have not been compensated for this article.